ct26 murine colon cancer cells  (ATCC)

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Comparison of systemic delivery of FusOn-CD47-luc and FusOn-luc in immune-competent mice pre-immunized with HSV-2 (A) Schematic illustration of the FusOn-series viruses used in this study. The parental FusOn-H2 was generated by replacing the N-terminal domain of the ICP10 gene, which encodes the large subunit of ribonucleotide reductase (RR), with GFP. The locations of glycoprotein C (gC), the terminal repeat long (TR L ) and short (TR S ) regions, and the internal repeats (IR) are indicated. FusOn-luc was constructed by inserting a luciferase gene cassette ( luc ) upstream of the gC locus, whereas FusOn-CD47-luc was generated by fusing the extracellular domain (ECD) of CD47 to gC and inserting the luc cassette at the same position. (B) IVIS imaging of virus distribution following systemic delivery. Balb/c mice were first immunized twice with a gH-deleted infectious single-cycle HSV-2 (DISC-HSV2) before implantation with CT26 tumor cells in the right flank. Once tumors reached approximately 8 mm in diameter, mice received one of the three viruses via tail vein injection at a dose of 2 × 10 6 PFU. Bioluminescence imaging was performed using an IVIS imager on the indicated days post-injection. The locations of the liver and tumor are indicated by red arrows. Representative images from one of five mice in each treatment group are shown.

Article Snippet: African green monkey kidney (Vero) cells, CT26 murine colon cancer cells, LL/2 murine lung cancer cells, and HCT116 human colorectal cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA).

Techniques: Comparison, Generated, Construct, Luciferase, Imaging, Virus, Injection

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: Tumor delivery efficiency of FusOn-SD following systemic delivery in vivo (A) Sequential images of one representative mouse from each group (five mice per group) at the indicated time points after systemic administration of FusOn-SD in immune-competent, CT26-tumor-bearing Balb/c mice pre-immunized with HSV-2. The experimental procedure was identical to that in B. (B) Effect of adoptively transferred human anti-HSV-2 sera on the systemic delivery of FusOn-SD to xenografted human tumors. Mpanc-96 human pancreatic cancer cells were implanted in the right flank of immunodeficient mice. Once tumors reached an approximate size of 8 mm in diameter, mice received an adoptive transfer of 100 μL of either a mixture of eight human anti-HSV-2 sera or non-immune sera as a control, followed by tail vein injection of 2 × 10 6 PFU FusOn-SD. Shown are IVIS images taken 48 h after virus administration, with the tumor sites and corresponding bioluminescent signals highlighted by red circles.

Article Snippet: African green monkey kidney (Vero) cells, CT26 murine colon cancer cells, LL/2 murine lung cancer cells, and HCT116 human colorectal cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA).

Techniques: In Vivo, Adoptive Transfer Assay, Control, Injection, Virus

Journal: Molecular Therapy Oncology

Article Title: Strategically engineering an oncolytic herpes simplex virus to improve systemic delivery

doi: 10.1016/j.omton.2026.201132

Figure Lengend Snippet: In vivo evaluation of the antitumor effect of FusOn-SD in immune syngeneic tumor models in immune-competent animals (A) Evaluation of FusOn-SD in the murine CT26 colon cancer model. Immune-competent Balb/c mice were immunized with HSV-2 before CT26 cells were implanted subcutaneously. Oncolytic viruses were given intratumorally at a dose of 2 × 10 6 PFU. Tumor size was measured at the indicated time points and plotted. ★ p < 0.05 compared with other oncolytic viruses and PBS; p < 0.05 compared with PBS. (B) Evaluation of FusOn-SD in the murine LL/2 lung cancer model. Immune-competent C57BL6 mice were immunized with HSV-2 before LL/2 cells were implanted subcutaneously. When tumor became palpable, 2 × 10 6 PFU of the indicated oncolytic viruses were given via the tail vein, either alone or in combination with CP and/or PD1 mAb (detailed treatment schemes are provided in the section). Tumor size was measured at the indicated time points and plotted. Due to the rapid growth of these two tumor models in the control group, the experiments were terminated early to address ethical concerns for animal welfare. ★ p < 0.05 compared with other treatment groups and PBS; p < 0.05 compared with PBS.

Article Snippet: African green monkey kidney (Vero) cells, CT26 murine colon cancer cells, LL/2 murine lung cancer cells, and HCT116 human colorectal cancer cells were purchased from the American Type Culture Collection (ATCC, Manassas, VA).

Techniques: In Vivo, Control

Journal: Frontiers in Veterinary Science

Article Title: Detection of bimodal survivin expressions in canine cancer types by flow cytometry compared to immunohistochemistry

doi: 10.3389/fvets.2025.1552415

Figure Lengend Snippet: Analysis of survivin expression sites by IHC and WB. (A) Images of HE staining and survivin expression via IHC in canine melanoma cell lines (CMM2, CMeC, and LMeC) are shown. (B) Images of HE staining and survivin expression via IHC in murine cell lines (p815, CT26, and B16F10) are shown. (C) The cytosol and total survivin expression patterns via WB are indicated. (D) The expression levels of total survivin (blue bar) and cytosolic survivin (orange bar) corrected on the basis of β-actin expression are shown via density of plot analysis via ImageJ software.

Article Snippet: A total of six cell lines were used: canine malignant melanoma lines [CMM2, CMeC2, LMeC; provided by Dr. Takayuki Nakagawa, Department of Veterinary Surgery, University of Tokyo; ( )], the murine malignant melanoma line B16F10, the murine mast cell tumor line p815, and the murine colon cancer line CT26 (distributed for a fee by the JCRB Cell Bank).

Techniques: Expressing, Staining, Software